EX-99.2

Fourth Quarter 2013

Earnings Conference Call Supplement

(Unaudited Results)

Jerome A. Peribere –

President & CEO

Carol P. Lowe –

Senior Vice President & CFO

Exhibit 99.2

Safe Harbor and Regulation G Statement

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform

Act of 1995. Forward-looking statements can be identified by such words as “anticipates,” “believes,” “plan,” “assumes,”

“could,” “estimates,” “expects,” “intends,” “may,” “plans to,” “will” and similar expressions. These statements reflect our

beliefs and expectations as to future events and trends affecting our business, our consolidated financial position and

our results of operations. Examples of these forward-looking statements include expectations regarding our anticipated

effective income tax rate, the potential cash tax benefits associated with the W. R. Grace settlement, potential volume,

revenue and operating growth for future periods, expectations and assumptions associated with our restructuring

programs, availability and pricing of raw materials, success of our growth initiatives, economic conditions, and the

success of pricing actions. A variety of factors may cause actual results to differ materially from these expectations,

including general domestic and international economic and political conditions, changes in our raw material and energy

costs, credit ratings, the success of restructuring plans, currency translation and devaluation effects, the competitive

environment, the effects of animal and food-related health issues, environmental matters, and regulatory actions and

legal matters. For more extensive information, see “Risk Factors” and “Cautionary Notice Regarding Forward-Looking

Statements,” which appear in our most recent Annual Report on Form 10-K, as filed with the Securities and Exchange

Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any

obligation to do so, whether as a result of new information, future events, or otherwise.

Our management uses non-U.S. GAAP financial measures to evaluate the Company’s performance, which exclude

items we consider unusual or special items. We believe the use of such financial measures and information may be

useful to investors. We believe that the use of non-U.S. GAAP measures helps investors to gain a better understanding

of core operating results and future prospects, consistent with how management measures and forecasts the

Company's performance, especially when comparing such results to previous periods or forecasts. Please see Sealed

Air’s February 6, 2014 earnings press release for important information about the use of non-U.S. GAAP financial

measures relevant to this presentation, including applicable reconciliations to U.S. GAAP financial measures.

Key Takeaways

FOURTH QUARTER & FULL YEAR 2013

Fourth Quarter 2013

•

Constant currency net sales growth of 4.1% with growth in all regions

•

Favorable product price/mix across all divisions and all regions

Full Year 2013

•

Constant currency net sales growth of 2.7% with growth in all divisions and all

regions, except Europe

•

Adjusted EBITDA, excluding SARs, increased 7.3% due to favorable pricing

and cost savings initiatives

•

Second time in eleven years, Sealed Air delivered Adj. EBITDA margin growth

•

Generated $509 million of Free Cash Flow

February 3, 2014

•

Completion of W. R. Grace & Co. Settlement agreement is a significant

milestone for Sealed Air, creating financial flexibility and additional cash

generation in future years

Reported U.S. GAAP Measures, Continuing Operations

Q4-13 Net Sales: $2.0B; Operating Profit: $172.6M; Net Income: $3.6M

2013 Net Sales: $7.7B; Operating Profit: $602.1M; Net Income: $93.7M

Q4-12 Net Sales: $2.0B; Operating Loss*: ($420.0M); Net Loss: ($345.2M)

2012 Net Sales: $7.6B; Operating Loss*: ($1.4B); Net Loss: ($1.9B)

*Includes impairment of goodwill and certain intangible assets associated with the Diversey acquisition

* Constant currency refers to unit volume and price/mix performance and excludes the impact of currency translation

Regional Sales Performance

FOURTH QUARTER 2013

Q4 Net Sales: $2.0B

Reported Sales Growth: Up 3.0%; Constant Currency: Up 4.1%

Latin

America

Reported: (1.3%)

Constant Currency: 6.7%

% of Sales: 10.7%

North

America

Reported: 3.1%

Constant Currency: 3.6%

% of Sales: 38.4%

Japan/ANZ

Reported: (6.0%)

Constant Currency: 2.7%

% of Sales: 7.8%

Europe

Reported: 6.1%

Constant Currency: 2.6%

% of Sales: 32.6%

AMAT

Reported: 4.2%

Constant Currency: 8.0%

% of Sales: 10.5%

Regional Sales Performance

FULL YEAR 2013

* Constant currency refers to unit volume and price/mix performance and excludes the impact of currency translation

2013 Net Sales: $7.7B

Reported Sales Growth: Up 1.7%; Constant Currency: Up 2.7%

Latin

America

Reported: 3.1%

Constant Currency: 9.7%

% of Sales: 10.7%

North

America

Reported: 1.8%

Constant Currency: 2.1%

% of Sales: 39.1%

Japan/ANZ

Reported: (5.2%)

Constant Currency: 0.5%

% of Sales: 7.4%

Europe

Reported: 1.2%

Constant Currency: (0.3%)

% of Sales: 31.8%

AMAT

Reported: 6.5%

Constant Currency: 8.8%

% of Sales: 11.0%

Net Sales Performance

Product Price/Mix & Volume

By Division

Q4 2013

2013

By Division

Q4 2013

2013

Food Care

3.2%

1.6%

Food Care

1.0%

1.7%

Diversey Care

1.8%

1.5%

Diversey Care

1.1%

0.5%

Product Care

1.7%

(0.2%)

Product Care

3.1%

2.6%

Medical/New Ventures

13.3%

2.3%

Medical/New Ventures

(6.0%)

(1.2%)

Total

2.7%

1.2%

Total

1.4%

1.5%

By Region

Q4 2013

2013

By Region

Q4 2013

2013

North America

3.7%

1.5%

North America

(0.1%)

0.6%

Europe

0.2%

(0.2%)

Europe

2.4%

(0.1%)

Latin America

7.1%

5.1%

Latin America

(0.4%)

4.6%

AMAT

3.0%

2.0%

AMAT

5.0%

6.8%

JANZ

1.1%

(0.6%)

JANZ

1.6%

1.1%

Total

2.7%

1.2%

Total

1.4%

1.5%

Product Price/Mix (% Change)

Volume (% Change)

Favorable Price/Mix in every division and in every region in Q4 2013

Food Care

SALES GROWTH WITH FAVORABLE PRICE/MIX

Q4 Net Sales ($M)

Packaging

Hygiene

811

832

175

180

986

1,012

2013

SG&A

Volume

Cost

Synergies

2012

Q4 2012

Q4 2013

Packaging

Hygiene

3,049

3,106

691

705

3,740

3,811

2012

2013

Q4 Adjusted EBITDA, excluding SARs ($M)

SG&A

2013

Perf-

based

Incentive

Comp

2012

Volume

Cost

Synergies

* Other includes ($20M) supply chain costs primarily related to LIFO adjustment,

non-material inflation & timing of inventory adjustments; FX: ($1.4M)

Full Year Net Sales ($M)

Full Year Adjusted EBITDA, excluding SARs ($M)

* Other includes ($13M) supply chain costs primarily related to non-material inflation;

FX: ($3.9M)

Other /

FX*

Mix &

Price/Cost

Spread

Mix &

Price/Cost

Spread

Other /

FX*

-3

-8

-28

151

156

579

535

-21

-24

-13

Perf-

based

Incentive

Comp

Diversey Care

INCREASED ADJUSTED EBITDA , EXCLUDING SARs

2013

SG&A

-3

Volume

Cost

Synergies

2012

Perf-

based

Incentive

Comp

-6

-4

223

210

SG&A

-7

2013

-25

Perf-

based

Incentive

Comp

2012

-14

Volume

Cost

Synergies

Q4 Net Sales ($M)

Q4 Adjusted EBITDA, excluding SARs ($M)

Full Year Net Sales ($M)

Full Year Adjusted EBITDA, excluding SARs ($M)

* FX: ($1.2M)

* Other includes ($12M) supply chain costs primarily related to non-material inflation

& inventory obsolescence; Also includes bad debt allowance of ($4M) recorded in

Q3 for large customer in AMAT; FX: ($1.2M)

Other/

FX*

Mix &

Price/Cost

Spread

Other/

FX*

Mix &

Price/Cost

Spread

534

546

Q4 2012

Q4 2013

2,132

2,160

2012

2013

Product Care

STRONG VOLUME & POSITIVE PRICE/MIX IN Q4

SG&A

-2

Volume

Cost

Synergies

2012

-8

Perf-

based

Incentive

Comp

-2

2013

-17

Perf-

based

Incentive

Comp

-7

SG&A

-9

-6

Volume

2012

Cost

Synergies

Q4 Net Sales ($M)

Q4 Adjusted EBITDA, excluding SARs ($M)

Full Year Net Sales ($M)

Full Year Adjusted EBITDA, excluding SARs ($M)

* Other includes ($7M) supply chain costs primarily related to LIFO adjustment &

non-material inflation; FX: ($0.3M)

* Other ($12M) includes supply chain costs primarily related to LIFO adjustment &

non-material inflation; FX: ($1.0M)

407

424

Q4 2012

Q4 2013

1,578

1,608

2012

2013

247

250

Mix &

Price/Cost

Spread

Mix &

Price/Cost

Spread

Other/

FX*

Other/

FX*

Q4 2013 Net Sales

2,013

Foreign Exchange

-22

Price/Mix

+52

Volume

+27

Q4 2012 Net Sales

1,956

Q4 Net Sales ($M)

Full Year Net Sales ($M)

Q4 & 2013 Net Sales Bridge

7,691

2013 Net Sales

Foreign Exchange

-76

Price/Mix

+94

Volume

+114

2012 Net Sales

7,559

+3%

+2%

273

275

Volume

Q4 2012

Adj. EBITDA

-1%

Other/FX*

-42

-17

-7

Q4 Adj. EBITDA, excluding SARs ($M)

Full Year Adj. EBITDA, excluding SARs ($M)

1,073

112

1,000

Volume

2012

Adj. EBITDA

+7%

Other/FX*

-61

-25

-34

Q4 & 2013 Adj. EBITDA Bridge

* Others include ($46M) supply chain costs primarily related to non-material inflation; FX: ($5.9M)

Cost

Synergies

Mix & Price/

Cost Spread

SG&A/

Other

Perf-

based

Incentive

Comp

Q4 2013

Adj. EBITDA

Cost

Synergies

Mix & Price/

Cost Spread

SG&A/

Other

Perf-

based

Incentive

Comp

Q4 2013

Adj. EBITDA

* Others include ($31M) supply chain primarily related to LIFO adjustment, non-material inflation & timing of inventory adjustments; FX: ($2.2M)

SIGNIFICANT YoY IMPROVEMENT

($ in millions)

Year

Ended

December

Free Cash Flow

($ in millions)

Free Cash Flow

2012

2013

Adjusted Net Earnings

$193

$263

Depreciation and Amortization

317

308

Profit Sharing Expense

Settlement agreement & Other Non-Cash Interest

Restructuring Payments

(103)

(107)

Tax Payments

(109)

(111)

SARs Payments

(24)

(46)

Net change in working capital items*

(77)

Other

117

120

Cash Flow from Operations

$394

$625

Capital Expenditures

(123)

(116)

Free Cash Flow

$271

$509

Year Ended

December 31

* Accounts Receivable, Inventories & Accounts Payable

271

509

2012

2013

Adjusted EBITDA: $1.05B -

$1.07B

(D&A: $315M; Interest Expense: $295M)

Net Sales: Approx. $7.7B

(Organic growth offset by product rationalization and more than 2% unfavorable FX)

2014 Outlook

Adjusted EPS: $1.50 –

$1.60

(Anticipated core tax rate of approx. 25%)

Free Cash Flow: Approx. $410M

(Assumes: Approx. $170M capex, $150M cash restructuring and $280M cash interest expense)

Note:

Adjusted EBITDA, EPS and D&A guidance excludes the impact of special items.

Adjusted EPS also includes $0.12 benefit related to the Settlement agreement.

Q&A

Earnings Conference Call

Fourth Quarter 2013

Appendix

Q4 & 2013 Adj. EPS Calculation

Reported U.S. GAAP Measures :

•

(1)

Comprised of $38.9M of property and equipment

depreciation, $30.8M of amortization of intangibles and

$3.8M of share-based compensation, net of ($0.3M)

special items

(2)

2013 contributions to be made in Sealed Air common stock

($ in millions, except Adjusted EPS)

(1)

Comprised of $160.2M of property and equipment

depreciation, $123.2M of amortization of intangibles and

$24.1M of share-based compensation, net of ($5.3M)

special items

(2)

2013 contributions to be made in Sealed Air common stock

Q4 Adjusted EBITDA

$261.8

2013 Adjusted EBITDA

$1,034.6

Depreciation and amortization

(1)

73.2

Depreciation and amortization

(1)

302.2

Interest expense

91.6

Interest expense

361.0

Non-cash profit sharing expense

(2)

5.2

Non-cash profit sharing expense

(2)

34.7

Adjusted pre-tax earnings

$91.8

Adjusted pre-tax earnings

$336.7

Core taxes (20.0%)

18.4

Core taxes (21.8%)

73.5

Adjusted net earnings

$73.4

Adjusted net earnings

$263.2

Diluted Shares

213.9

Diluted Shares

213.5

Q4 Adjusted EPS

$0.34

2013 Adjusted EPS

$1.23

Q4 2013 Operating Income: $172.6M; Net Income: $3.6M; 2013 Operating Income: $602.1M; Net Income: $93.7M

Q4 2013: Recognized $0.11 in discontinued operations, including $0.10 per share gain on Medical Rigids sale

2013: Recognized $0.14 in discontinued operations, including $0.10 per share gain on Medical Rigids sale

Liquidity & Net Debt

($ in millions)

Liquidity Position

1,901

Net Debt

Lower net debt as a result of cash generated

from operating activities & asset sales,

partially offset by capital expenditures &

dividend payments

992

700

209

Dec. 31, 2013

Cash & Cash Equivalents

A/R Securitization

4,779

4,332

Dec. 31, 2012

Dec. 31, 2013

Revolving Credit Facility

GAAP Operating Profit (Loss)

(1)

2013

2012

2013

2012

Revised

(2)

Revised

(2)

Operating profit (loss):

Food Care

119.6

(95.0)

431.4

(170.9)

As a % of Food Care net sales

11.8

(9.6)

11.3

(4.6)

Diversey Care

11.2

(322.4)

57.9

(1,278.4)

As a % of Diversey Care net sales

2.1

(60.4)

2.7

(60.0)

Product Care

56.7

56.9

200.4

207.5

As a % of Product Care net sales

13.4

14.0

12.5

13.1

Other Category: Medical Applications business and New Ventures

(1.9)

(24.5)

(12.7)

(36.0)

As a % of Medical Applications and New Ventures net sales

(6.2)

(86.0)

(11.4)

(32.8)

Total segments and other category

185.6

(385.0)

677.0

(1,277.8)

As a % of total net sales

9.2

(19.7)

8.8

(16.9)

Costs related to the acquisition and integration of Diversey

0.4

2.6

1.1

7.4

Restructuring and other charges

12.6

32.4

73.8

142.5

Total

172.6

(420.0)

602.1

(1,427.7)

As a % of total net sales

8.6

(21.5)

7.8

(18.9)

December 31,

(Unaudited, $ in millions)

Year Ended

Three Months Ended

(1)

The supplementary information included in this press release for 2013 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form

10-K with the Securities and Exchange Commission.

(2)

In December 2013, we completed the sale of our Medical Rigids business. The financial results of the Medical Rigids business are reported as discontinued

operations, net of tax, and, accordingly all previously reported financial information has been revised.